GSK Releases 200 TB Compounds for Open Innovation

October 11, 2012 | GlaxoSmithKline has released access to 200 compounds with possible action against tuberculosis. The big pharma screened its compound library and these 200 compounds were flagged. Releasing them to external researchers is a move toward an "open innovation" approach to R&D. PM Live